Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial.

PLoS medicine - 1 Feb 2020

Fredsøe Jacob, Koetsenruyter Jan, Vedsted Peter, Kirkegaard Pia, Væth Michael, Edwards Adrian, Ørntoft Torben F, Sørensen Karina D, Bro Flemming

Abstract excerpt

BACKGROUND: Assessing genetic lifetime risk for prostate cancer has been proposed as a means of risk stratification to identify those for whom prostate-specific antigen (PSA) testing is likely to be most valuable. This project aimed to test the effect of introducing a genetic test for lifetime risk of prostate cancer in general practice on future PSA testing. METHODS AND FINDINGS: We performed a cluster...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Early Detection of Cancer
Share to Genetic Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kallikreins

Share to Logistic Models

Share to Primary Health Care

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 32032355
DOI: 10.1371/journal.pmed.1003033
PMCID: PMC7006905

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial.PMID 32032355Read ↗

Assessing the clinical utility of genetic risk scores for targeted cancer screening.Semantic proximity Read ↗

Improved prostate cancer prediction by combining Prostate-Specific Antigen (PSA) test results with Genetic Risk Scores (GRS/PRS)Semantic proximity Read ↗

Applying a genetic risk score for prostate cancer to men with lower urinary tract symptoms in primary care to predict prostate cancer diagnosis: a cohort study in the UK BiobankSemantic proximity Read ↗

Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational studySemantic proximity Read ↗

Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.Semantic proximity Read ↗

Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study.Semantic proximity Read ↗

Prostate cancer screening using risk stratification based on a multi-state model of genetic variants.Semantic proximity Read ↗

The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening.Semantic proximity Read ↗

Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study.Semantic proximity Read ↗

Psychosocial outcomes of risk-adapted prevention for prostate cancer predisposition: study protocol for a longitudinal observational mixed-methods study.Semantic proximity Read ↗

Initial Findings from a High Genetic Risk Prostate Cancer Clinic.Semantic proximity Read ↗

Hereditary cancer risk assessment and genetic testing in the community urology practice setting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.